ALBO News and Press, Albireo Pharma Inc. From 02/28/22

BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the hea...

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on March 1, 2022, to provide a bus...

– Decision provides access to the first drug treatment approved in PFIC for patients in England, Wales and Northern Ireland – Positive NICE review completed in less than six months post MHRA approval – NICE review is first successful clinical & e...

PFIC caregivers reported high impact on mental and physical health, productivity, career prospects, sleep, relationships and finances Study suggests PFIC caregivers’ quality of life may be comparable to that of cystic fibrosis caregivers BOSTON, Feb. 14, 2022 ...

The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...

– Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M – Unaudited cash of at least $248M, updates guidance with cash into 2024 – BOLD Phase 3 study in biliary atresia is over 50% enrolled – ASSERT Phase 3 study in Alagil...

– First oral, systemic ASBT inhibitor was safe and well tolerated – Secondary and exploratory objectives show favorable pharmacokinetics and systemic exposure, while providing target engagement signals – Company on track to initiate planned adult liv...

– Data show significant correlations in serum bile acid reductions and long-term improvements in pruritus and sleep – Reductions in serum bile acids and improvements in pruritus with and without concomitant ursodeoxycholic acid and/or rifampicin use and B...

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost ...